Ontology highlight
ABSTRACT:
SUBMITTER: Cho D
PROVIDER: S-EPMC3934425 | biostudies-literature | 2013 Jul-Aug
REPOSITORIES: biostudies-literature
Cancer journal (Sudbury, Mass.) 20130701 4
Allosteric inhibitors of the kinase mammalian target of rapamycin (mTOR) have demonstrated significant clinical activity in patients with advanced renal cell carcinoma (RCC). Unfortunately, substantial clinical responses to these rapalogues are seen only in a subset of patients with advanced RCC. Preclinical studies have identified multiple theoretical shortcomings of the rapalogues, and numerous novel agents directed against the phosphatidylinositol 3-kinase/Akt/mTOR pathway, which address many ...[more]